Comparative effectiveness of tocilizumab with either methotrexate or leflunomide in the treatment of rheumatoid arthritis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Narváez, Javier ^a   Díaz Torné, César ^b   Magallares, Berta ^b   Hernández, Maria Victoria ^c   Reina, Delia ^d   Corominas, Héctor ^d   Sanmartí, Raimon ^c   De La Serna, Arturo Rodriguez ^b   Llobet, Josep Maria ^b   Nolla, Joan M ^a  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^c INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^d Sant Joan de Déu Nursing s School University   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL PRODUCT; DISEASE MODIFYING ANTIRHEUMATIC DRUG; GLUCOCORTICOID; LEFLUNOMIDE; LIPID; LIVER ENZYME; METHOTREXATE; PREDNISONE; TOCILIZUMAB; ANTIRHEUMATIC AGENT; ISOXAZOLE DERIVATIVE; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BACTERIAL ARTHRITIS; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DISEASE ACTIVITY; DIVERTICULITIS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG FATALITY; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCARDITIS; FEMALE; FUNCTIONAL DISEASE; HUMAN; INFECTION; INFUSION RELATED REACTION; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; MIDDLE AGED; NEUTROPENIA; OBSERVATIONAL STUDY; PELVIC INFLAMMATORY DISEASE; PSORIASIS; RHEUMATOID ARTHRITIS; SALPINGITIS; SIDE EFFECT; TREATMENT DURATION; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; AGED; ARTHRITIS, RHEUMATOID; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; RETROSPECTIVE STUDY;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; ISOXAZOLES; MALE; METHOTREXATE; MIDDLE AGED; NEUTROPENIA; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 84926671951     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0123392     Document Type: Article

References (23)

1. Schoels MM, Van Der Heijde D, Breedveld FC, Burmester GR, Dougados M, Emery P, et al. Blocking the effects of interleukin-6 in rheumatoid arthritis and other inflammatory rheumatic diseases: systematic literature review and meta-analysis informing a consensus statement. Ann Rheum Dis 2013;72:583-9. doi: 10.1136/annrheumdis-2012-202470 PMID: 23144446
2. EMA. RoActemra (tocilizumab). Summary of product characteristics. Available: http://www.ema. europa.eu/docs/en GB/.document library/EPAR - Product Information/human/000955/WC500054890.pdf. Accessed: 2012 Mar. 15.
3. Nishimoto N, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, Azuma J, et al. Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy. Mod Rheumatol. 2009;19:12-9. doi: 10.1007/s10165-008-0125-1 PMID: 18979150
4. Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis 2007;66:1162-7 PMID: 17485422
5. Jones G, Sebba A, Gu J, Lowenstein MB, Calvo A, Gomez-Reino JJ, et al. Comparison of tocilizumab monotherapy versus methotrexate monotherapy in patients with moderate to severe rheumatoid arthritis: the AMBITION study. Ann Rheum Dis 2010;69:88-96. doi: 10.1136/ard.2008.105197 PMID: 19297346
6. Pers YM, Fortunet C, Constant E, Lambert J, Godfrin-Valnet M, De Jong A, et al. Predictors of response and remission in a large cohort of rheumatoid arthritis patients treated with tocilizumab in clinical practice. Rheumatology 2014;53:76-84. doi: 10.1093/rheumatology/ket301 PMID: 24056521
7. Takeuchi T, Kaneko Y, Atsumi T, Tanaka Y, Inoh M, Kobayashi H, et al. Adding tocilizumab or switching to tocilizumab monotherapy in rheumatoid arthritis patients with inadequate response to methotrexate: 24-week results from a randomized controlled study (SURPRISE study) [abstract]. Ann Rheum Dis 2013;72(Suppl3):62.
8. Dougados M, Kissel K, Sheeran T, Tak PP, Conaghan PG, Martín Mola E, et al. Adding tocilizumab or switching to tocilizumab monotherapy in methotrexate inadequate responders: 24-week symptomatic and structural results of a 2-year randomised controlled strategy trial in rheumatoid arthritis (ACT-RAY). Ann Rheum Dis 2013;72:43-50. doi: 10.1136/annrheumdis-2011-201282 PMID: 22562983
9. Takeuchi T, Kaneko Y, Atsumi T, Tanaka Y, Inoh M, Kobayashi H, et al. Clinical and radiographic effects after 52-week of adding tocilizumab or switching to tocilizumab in rheumatoid arthritis patients with inadequate response to methotrexate: results from a prospective randomized controlled study (SURPRISE study) [abstract]. Ann Rheum Dis 2014;73(Suppl2)
10. Dougados M, Kissel K, Conaghan PG, Martín Mola E, Schett G, Gerli R, et al. Clinical, radiographic and immunogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73:803-9. doi: 10.1136/annrheumdis-2013-204761 PMID: 24473673
11. Kojima T, Yabe Y, Kaneko A, Takahashi N, Funahashi K, Kato D, et al. Importance of methotrexate therapy concomitant with tocilizumab treatment in achieving better clinical outcomes for rheumatoid arthritis patients with high disease activity: an observational cohort study. Rheumatology 2014 Aug. 7. pii: keu302. [Epub ahead of print]
12. Nam JL, Ramiro S, Gaujoux-Viala C, Takase K, Leon-Garcia M, Emery P, et al. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2013 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2014;73:516-28. doi: 10.1136/annrheumdis-2013-204577 PMID: 24399231
13. Behrens F, Koehm M, Burkhardt H. Update 2011: leflunomide in rheumatoid arthritis-strengths and weaknesses. CurrOpin Rheumatol 2011;23:282-7. doi: 10.1097/BOR.0b013e328344fddb PMID: 21427581
14. De Stefano R, Frati E, Nargi F, Baldi C, Menza L, Hammoud M, et al. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 2010;29:517-24. doi: 10.1007/s10067-009-1349-y PMID: 20082236
15. Finckh A, Dehler S, Gabay C; SCQM doctors. The effectiveness of leflunomide as a co-therapy of tumour necrosis factor inhibitors inrheumatoid arthritis: a population-based study. Ann Rheum Dis 2009;68:33-9. doi: 10.1136/ard.2007.085696 PMID: 18230627
16. Richter A, Strangfeld A, Herzer P, Wilden E, Bussmann A, Listing J, et al. Sustainability of rituximab therapy in different treatment strategies-results of a 3-year follow-up of the German biologics register RABBIT. Arthritis Care Res 2014 Mar. 24. doi: 10.1002/acr.22327. [Epub ahead of print].
17. Narváez J, Díaz-TornéC, Ruiz JM, Hernández MV, Torrente-Segarra V, Ros S, et al. Comparative effectiveness of rituximab in combination with either methotrexate or leflunomide in the treatment of rheumatoid arthritis. Semin Arthritis Rheum 2011;41:401-5. doi: 10.1016/j.semarthrit.2011.06.005 PMID: 21862107
18. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, Tarp U, et al. Effectiveness of diseasemodifying antirheumatic drug co-therapy with methotrexate and leflunomide in rituximab-treated rheumatoid arthritis patients: results of a 1-year follow-up study from the CERERRA collaboration. Ann Rheum Dis 2012;71:374-7. doi: 10.1136/annrheumdis-2011-200003 PMID: 21972242
19. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS, et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24. PMID: 3358796
20. Smolen JS, Landewé R, Breedveld FC, Buch M, Burmester G, Dougados M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014;73:492-509. doi: 10.1136/annrheumdis-2013-204573 PMID: 24161836
21. Tornero Molina J, SanmartíSala R, Rodríguez Valverde V, Martín Mola E, Marenco De La Fuente JL, González Álvaro I, et al. Update of the Consensus Statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis. Reumatol Clin 2010;6:23-36. doi: 10. 1016/j.reuma.2009.10.006 PMID: 21794674
22. Genovese MC, McKay JD, Nasonov EL, Mysler EF, Da Silva NA, Alecock E, et al. Interleukin-6 receptor inhibition with tocilizumab reduces disease activity in rheumatoid arthritis with inadequate response to disease-modifying antirheumatic drugs: thetocilizumab in combination with traditional disease-modifying antirheumatic drug therapy study. Arthritis Rheum 2008;58:2968-80 doi: 10.1002/art.23940 PMID: 18821691
23. Burmester GR, Feist E, Kellner H, Braun J, Iking-Konert C, Rubbert-Roth A. Effectiveness and safety of the interleukin 6-receptor antagonist tocilizumab after 4 and 24 weeks in patients with active rheumatoid arthritis: the first phase IIIb real-life study (TAMARA). Ann Rheum Dis. 2011;70:755-9. doi: 10.1136/ard.2010.139725 PMID: 21187298